Page last updated: 2024-12-07
albizziin
Description
Albizziin is a non-protein amino acid that was first isolated from the plant Albizzia saman. It is a potent inhibitor of glutamate decarboxylase, the enzyme responsible for converting glutamate to GABA. This inhibition leads to increased levels of glutamate in the brain, which can have neurotoxic effects. Albizziin has also been shown to have anti-inflammatory and anti-tumor activity. Due to its potent biological activity, albizziin has been studied for its potential therapeutic applications in treating neurological disorders, cancer, and inflammation. The synthesis of albizziin involves a complex multi-step process that starts from the amino acid L-glutamine. Albizziin is an interesting molecule due to its unique structure and its potent biological activity. It is a promising target for the development of new drugs for the treatment of a wide range of diseases.'
albizziin: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 92891 |
CHEBI ID | 6173 |
SCHEMBL ID | 690347 |
MeSH ID | M0049023 |
Synonyms (55)
Synonym |
nsc-132089 |
albizzine |
l-albizziin |
l-alanine, 3-[(aminocarbonyl)amino]- |
l-2-amino-3-ureidopropionic acid |
C08264 |
albizziin |
l-albizziine |
1483-07-4 |
A-4650 |
zinc01531037 |
(2s)-2-amino-3-(carbamoylamino)propanoic acid |
A808754 , |
(s)-2-amino-3-ureidopropanoicacid |
AKOS006237907 |
3-ureido-l-alanin |
l-alanine, 3-((aminocarbonyl)amino)- |
albizziin (van) |
nsc 132089 |
einecs 216-046-1 |
l-beta-ureidoalanine |
rw59as48cr , |
unii-rw59as48cr |
l-(-)-2-amino-3-ureidopropionic acid |
propionic acid, 2-amino-3-ureido-, l- |
nsc 407273 |
albizziin [mi] |
3-((aminocarbonyl)amino)-l-alanine |
SCHEMBL690347 |
CHEBI:6173 |
(2s)-2-amino-3-ureido-propanoic acid |
3-[(aminocarbonyl)amino]alanine # |
GZYFIMLSHBLMKF-REOHCLBHSA-N |
(2s)-2-ammonio-3-(carbamoylamino)propanoate |
(2s)-3-(aminocarbonylamino)-2-azaniumyl-propanoate |
c4h9n3o3 |
albizziin (h-dap(conh2)-oh) |
mfcd00007952 |
l-(-)2-amino-3-ureidopropionic acid |
h-beta-(ureido)-ala-oh |
AS-63003 |
C90278 |
albizziin, aldrichcpr |
h--((aminocarbonyl)amino)-ala-oh;h-dap(carbamoyl)-oh |
(s)-2-amino-3-ureidopropanoic acid |
Q27107112 |
AMY22571 |
HY-121167 |
butyl 4-?hydroxybenzoate |
(butyl paraben) |
DTXSID501318659 |
EN300-7026825 |
CS-0079579 |
nsc823850 |
nsc-823850 |
Drug Classes (1)
Class | Description |
non-proteinogenic L-alpha-amino acid | Any L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (57.14) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 17.39 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.40 (4.65) | Search Engine Demand Index | 10.37 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |